Adaptaquin

Adaptaquin is a BBB-penetrable HIF-PHDs inhibitor. Adaptaquin has anti-inflammatory and neuroprotective effects. Adaptaquin can effectively inhibit lipid peroxidation, maintain mitochondrial function, and reduce neuronal death. Adaptaquin can be used in the research of nervous system diseases such as Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[385786-48-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

HIF/HIF Prolyl-Hydroxylase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/adaptaquin.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C2N=CC=CC2=CC=C1C(C3=CC=C(Cl)C=C3)NC4=NC=CC=C4O

Molecular Formula

C21H16ClN3O2

Molecular Weight

377.82

Precautions

H302, H315, H319

References & Citations

[1]Neitemeier S, et, al. Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis. Cell Death Dis. 2016 May 5;7 (5) :e2214.|[2]Aimé P, et al. The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson's disease. Neurobiol Dis. 2020 Mar;136:104725.|[3]Karuppagounder SS, et al. Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med. 2016 Mar 2;8 (328) :328ra29.